The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy.
A single patient who had a leukemic relapse six months after receiving a syngeneic bone marrow transplant was given "adoptive chemoimmunotherapy." Lymphocytes from the patients identical twin were alloactivated and grown in T cell growth factor in vitro. After receiving chemotherapy to reduce the number of relapsed leukemia cells, he received 1.1 X 10(10) in vitro alloactivated twin lymphocytes via intravenous and intraperitoneal injections. Although progressive Candidal pneumonia was fatal and prevented analysis of either efficacy or delayed toxicity of this potential form of therapy for this patient, radioactive 111In labelling and scanning showed dissemination of these lymphocytes following either injection route, with no clinical evidence of immediate toxicity.
D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007204:Indium; D007376:Interleukin-2 / Q000494:pharmacology; D007948:Leukemia, Monocytic, Acute / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D011247:Pregnancy; D011868:Radioisotopes; D014430:Twins, Monozygotic
D007376:Interleukin-2; D011868:Radioisotopes; D007204:Indium